Jazz Pharmaceuticals (NASDAQ:JAZZ) Given New $113.00 Price Target at UBS Group

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its target price decreased by UBS Group from $117.00 to $113.00 in a research note issued to investors on Tuesday morning, Benzinga reports. UBS Group currently has a neutral rating on the specialty pharmaceutical company’s stock.

JAZZ has been the topic of several other research reports. JPMorgan Chase & Co. lifted their price objective on Jazz Pharmaceuticals from $170.00 to $190.00 and gave the stock an overweight rating in a report on Friday, March 22nd. HC Wainwright reissued a buy rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a report on Friday, May 3rd. The Goldman Sachs Group began coverage on shares of Jazz Pharmaceuticals in a research note on Wednesday, June 5th. They issued a buy rating and a $169.00 price objective for the company. Cantor Fitzgerald reissued an overweight rating and issued a $180.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, April 10th. Finally, Barclays dropped their price target on shares of Jazz Pharmaceuticals from $230.00 to $200.00 and set an overweight rating for the company in a research report on Friday, May 3rd. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of Moderate Buy and an average target price of $188.62.

Jazz Pharmaceuticals Trading Down 2.2 %

Shares of Jazz Pharmaceuticals stock opened at $101.27 on Tuesday. The company has a market cap of $6.39 billion, a price-to-earnings ratio of 20.88, a PEG ratio of 1.59 and a beta of 0.58. Jazz Pharmaceuticals has a 1 year low of $100.34 and a 1 year high of $146.70. The company’s fifty day simple moving average is $108.46 and its 200-day simple moving average is $116.12. The company has a current ratio of 2.27, a quick ratio of 1.90 and a debt-to-equity ratio of 1.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.53 by ($1.55). The company had revenue of $901.98 million for the quarter, compared to the consensus estimate of $938.99 million. Jazz Pharmaceuticals had a return on equity of 27.86% and a net margin of 8.61%. As a group, sell-side analysts expect that Jazz Pharmaceuticals will post 15.35 EPS for the current year.

Insider Activity at Jazz Pharmaceuticals

In related news, EVP Neena M. Patil sold 5,000 shares of the company’s stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $109.65, for a total value of $548,250.00. Following the completion of the sale, the executive vice president now owns 36,629 shares in the company, valued at $4,016,369.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 4.20% of the stock is owned by company insiders.

Institutional Trading of Jazz Pharmaceuticals

Large investors have recently made changes to their positions in the company. Rise Advisors LLC boosted its position in Jazz Pharmaceuticals by 2,255.6% during the 1st quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company’s stock worth $26,000 after acquiring an additional 203 shares during the last quarter. GAMMA Investing LLC grew its holdings in Jazz Pharmaceuticals by 65.5% in the 2nd quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock valued at $31,000 after buying an additional 116 shares in the last quarter. Cape Investment Advisory Inc. increased its position in Jazz Pharmaceuticals by 14,600.0% during the fourth quarter. Cape Investment Advisory Inc. now owns 294 shares of the specialty pharmaceutical company’s stock worth $36,000 after acquiring an additional 292 shares during the period. Assetmark Inc. boosted its holdings in Jazz Pharmaceuticals by 37.1% in the 4th quarter. Assetmark Inc. now owns 440 shares of the specialty pharmaceutical company’s stock valued at $54,000 after purchasing an additional 119 shares during the period. Finally, Headinvest LLC acquired a new position in shares of Jazz Pharmaceuticals during the 3rd quarter worth approximately $56,000. Institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.